Iterum Therapeutics expands ORLYNVAH coverage to 40 million lives in 2026.

Iterum Therapeutics, a company focused on oral and IV antibiotics, has provided a business update. The company has finalized a commercial contract with a Group Purchasing Organization that collaborates with a major Pharmacy Benefit Manager, adding coverage opportunities for over 40 million lives starting in early 2026. This milestone underscores the growing acceptance of ORLYNVAH across the payor landscape. Iterum plans to launch targeted pull-through campaigns in Q1 2026.